TABLE 4.
Surface IL-10 receptor expression [%] | TGF-β release [pg/mL] | IL-6 release [%] | TNF-α release [%] | |
---|---|---|---|---|
Control | 100.2 ± 21.6 | 33.7 ± 7.9 a | 34.4 ± 4.2 | 24.3 ± 5.4 |
Stimulation (+LPS) | 46.4 ± 15.5 a | 8.5 ± 4.8 a | 100.0 ± 2.1 a | 100.4 ± 3.3 a |
G. squarrosa extract + LPS | ||||
25 μg/ml | 257.4 ± 61.8 d | 37.5 ± 2.1 | 64.3 ± 6.2 d | 58.5 ± 2.5 d |
50 μg/ml | 476.6 ± 62.4 d | 43.6 ± 4.8 | 60.2 ± 4.4 d | 55.3 ± 3.8 d |
100 μg/ml | 904.3 ± 96.4 d | 58.4 ± 4.4 c | 52.5 ± 2.2 d | 45.2 ± 2.8 d |
Grindelic acid + LPS | ||||
10 µM | 13.8 ± 3.6 | n.d | 87.9 ± 4.7 | 90.4 ± 3.3 |
20 µM | 16.5 ± 5.5 | n.d | 84.4 ± 8.2 | 85.3 ± 2.7 |
50 µM | 18.1 ± 6.2 | 35.3 ± 9.8 | 74.3 ± 3.5 c | 76.6 ± 0.9 |
100 μg/ml | ||||
Budesonide 50 µM | 50.0 ± 5.6 | 40.3 ± 2.1 | 56.4 ± 3.8 d | 65.9 ± 1.6 d |
Clarithromycin 50 µM | 64.4 ± 4.7 | n.d | 68.4 ± 6.6 c | 78.6 ± 2.1 b |
n.d., not detectable.
p < 0.01 vs. not stimulated cells;
p < 0.05 vs. LPS-stimulated cells;
p < 0.01 vs. LPS-stimulated cells;
p < 0.001 vs. LPS-stimulated cells.